Stem cell composite material and application thereof

Through stem cell composite materials, the use of porous microspheres loaded with curcumin combined with bone marrow mesenchymal stem cells has solved the problem of wound healing in diabetic patients, achieved the sustained release of curcumin and the maintenance of stem cell activity, and significantly promoted the diabetic foot Healing and collagen remodeling.

CN118903203APending Publication Date: 2024-11-08MUDANJIANG MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310507954.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-08
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The difficulty in wound healing in diabetic patients is mainly due to angiogenesis disorders and loss of microvascular function. The existing treatment methods are difficult to cure, and the poor water solubility and biological instability of curcumin limit its application.

Method used

Develop a stem cell composite material that uses porous microspheres loaded with curcumin as a drug-loading system, combines bone marrow mesenchymal stem cells, and slowly releases curcumin through diffusion and decreasing mechanisms, promotes cell adhesion and maintains stem cell activity. Treatment of diabetic foot.

Benefits of technology

It significantly promotes the healing of difficult-to-heal wounds in diabetes, improves collagen remodeling and skin maturity, improves stem cell survival and activity, and overcomes the solubility and stability of curcumin.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004216216690000071
    Figure BDA0004216216690000071
  • Figure BDA0004216216690000101
    Figure BDA0004216216690000101
  • Figure BDA0004216216690000102
    Figure BDA0004216216690000102
Patent Text Reader

Abstract

The invention relates to the technical field of biological stem cells, in particular to a stem cell composite material and application thereof. The stem cell composite material comprises a drug loading system and mesenchymal stem cells loaded on the drug loading system, wherein the drug loading system is porous microspheres loaded with curcumin; the material of the porous microspheres in the porous microspheres loaded with the curcumin is four-arm star-shaped polylactide; the mesenchymal stem cells are preferably bone marrow mesenchymal stem cells. The porous microspheres loaded with curcumin are used as a novel medicine system of mesenchymal stem cells, cell adhesion can be promoted, the activity of the stem cells can be maintained, it is found that the stem cell composite material can induce efficient collagen remodeling and skin maturation, and the obvious treatment effect on diabetic wounds difficult to heal is achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of biological stem cells, and in particular to a stem cell composite material and application thereof. Background Art

[0002] Diabetes mellitus (DM) includes a group of metabolic diseases caused by changes in the secretion and action of insulin produced by the pancreas. Its main characteristics are hyperglycemia associated with abnormal functions of various systems such as cardiovascular, renal and nervous systems, such as diabetic foot disease (DFU) and diabetic nephropathy.

[0003] The microscopic pathological manifestations of skin lesions in diabetic patients are mainly abnormal cell phenotypes, including reduced potential for cell mitosis and loss of the ability to respond to the surrounding environment. Diabetes is one of the most common diseases in the world. About 20% of diabetic patients may have difficulty healing wounds. Diabetic foot caused by difficult diabetic wound healing is the most serious complication. The risk of foot ulcers in diabetic patients during their lifetime is 25%. The incidence of diabetic foot among diabetic patients worldwide is about 6.4%, and 1% of diabetic patients have to undergo amputation or even death due to foot lesions, which is the most expensive diabetic complication.

[0004] While peripheral neuropathy, peripheral arterial disease, and trauma are major factors contributing to the development of foot ulcers, impaired wound healing is the major complication that leads to the development of chronic wounds, often leading to amputation. Diabetes is the most common cause of non-traumatic lower limb amputation. Microcirculatory defects often accompany peripheral neuropathy and peripheral arterial disease, contributing to the development of diabetic foot problems. In addition, several anatomical foot deformities, which impair loading of the plantar surface, have also been associated with impaired wound healing in diabetic patients. Furthermore, diabetes alters the immune response and reduces resistance to infection. Therefore, diabetic wound infection further impairs healing through multiple mechanisms.

[0005] The skin is one of the largest organs in the human body and plays an integral role in maintaining homeostasis with the surrounding world through three key functions: regulation, protection and sensation. In most cases, in young, healthy patients, wounds heal successfully and normal skin function is restored. However, patients who are older or have a range of medical conditions such as cardiovascular disease, diabetes or obesity have significantly higher impairments in wound healing mechanisms. Wound healing is a dynamic and complex biological process that can be divided into four partially overlapping phases: hemostasis, inflammation, proliferation and remodeling. These phases involve a large number of cell types, extracellular components, growth factors and cytokines. Diabetes leads to impaired wound healing through biological mechanisms that affect one or more of these processes. It is usually caused by hyperglycemia, chronic inflammation, microcirculatory and macrocirculatory dysfunction, hypoxia, autonomic and sensory neuropathy, and impaired neuropeptide signaling.

[0006] At present, the main principles of diabetic foot treatment are wound debridement, decompression, revascularization and infection management. However, these treatment options still have the defects of treating symptoms but not the root cause and are difficult to cure. The main reason why diabetic ulcer wounds are difficult to heal is angiogenesis disorders and loss of microvascular function. It is particularly important to repair diabetic ulcer wounds and restore the function and structure of microvessels.

[0007] Curcumin has been proposed as a therapeutic drug that can enhance the patient's repair ability and promote their unhealed wounds. Curcumin is derived from the plant turmeric and has anti-inflammatory, antioxidant, antibacterial, anti-tumor and anti-diabetic pharmacological effects. It can promote skin wound healing through its anti-inflammatory, antioxidant and cell migration promoting effects. In the field of regenerative medicine, curcumin has attracted much attention for its pro-angiogenic and immunomodulatory properties. Liu et al. have shown that turmeric can basically completely reverse the increase of intracellular oxidative free radicals caused by hydrogen peroxide and reverse the trend of reduced GSH decline, thereby blocking the oxidative damage of a certain concentration of hydrogen peroxide. Curcumin can inhibit the growth of tumor cells by inhibiting the cell cycle and promoting cell apoptosis, inhibiting the expression of anti-apoptotic proteins and various signaling pathway proteins related to cell survival. Curcumin can induce P53-dependent and non-P53-dependent G2 / M phase cell cycle arrest, thereby limiting the proliferation of tumor cells. Curcumin has been shown to improve the oxidative stress state of cells, and the changes in molecular markers of oxidative stress can be verified experimentally. However, its application is limited due to its poor water solubility, biological instability, and poor bioavailability.

[0008] The current results show that mesenchymal stem cells promote wound healing in diabetic mice through differentiation, angiogenesis, and impaired glucose metabolism. Therefore, the use of mesenchymal stem cell transplantation to repair diabetic wounds is a potential clinical application approach. Bone marrow mesenchymal stem cells are naturally present in human tissues (so-called adult stem cells) and help maintain and repair damaged tissues. Studies have shown that innate MSCs are recruited to sites of tissue damage and activated by the inflammatory environment and close interaction with the immune system, a process known as permissiveness. Under these environmental cues, MSCs secrete a large number of cytokines and growth factors, changing the composition of local cytokines, which is thought to be beneficial for wound healing and tissue remodeling. In addition, MSCs promote wound healing by promoting angiogenesis, inhibiting inflammation, and promoting fibroblast migration and collagen production through paracrine mechanisms. All of these properties are considered key to rapid and effective wound healing, and it is believed that MSCs may be useful in treating difficult-to-heal wounds, reducing inflammation, accelerating skin healing, restoring barrier function, and reducing scars. In the field of regenerative medicine, MSCs have attracted much attention due to their pro-angiogenic and immunomodulatory properties. However, a major problem limiting the efficacy of mesenchymal stem cells is the low survival rate and activity after transplantation.

[0009] In view of this, the present invention is proposed. Summary of the invention

[0010] In order to solve the above technical problems, the present invention provides a stem cell composite material which can be used as a drug for treating diabetic foot and its application.

[0011] The present invention provides a stem cell composite material, comprising a drug-carrying system and mesenchymal stem cells loaded on the drug-carrying system, wherein the drug-carrying system is a porous microsphere loaded with curcumin; the material of the porous microspheres in the porous microspheres loaded with curcumin is four-arm star-shaped polylactide; preferably, the mesenchymal stem cells are preferably bone marrow mesenchymal stem cells.

[0012] The present invention provides application of the stem cell composite material in preparing a medicine for treating diabetic foot.

[0013] The present invention provides application of the above stem cell composite material in preparing a medicine for treating and promoting wound healing.

[0014] The technical solution provided by the embodiment of the present invention has the following advantages compared with the prior art:

[0015] The present invention uses porous microspheres loaded with curcumin as a new drug system for mesenchymal stem cells, which can promote cell adhesion and maintain stem cell activity. It is found that the stem cell composite material can induce efficient collagen remodeling and skin maturation, and has a significant therapeutic effect on diabetic difficult-to-heal wounds. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 Laser confocal microscope was used to observe the morphology of curcumin-loaded bouquet microspheres;

[0017] Figure 2 The scanning electron microscope images of FPM, Figure A is the electron microscope image of FPM; Figures B and C are magnified details of FPM;

[0018] Figure 3 Figure 1 is a scanning electron microscope image of CFPM, Figure D is an electron microscope image; Figures E and F are magnified details of CFPM;

[0019] Figure 4 is the cumulative release graph of curcumin by CFPM;

[0020] Figure 5Figure 1 shows the identification of stem cell tri-differentiation and flow cytometry: Figure A shows the morphology of bone marrow mesenchymal stem cells, magnification 100×; Figure B shows the identification of adipocytes by Oil Red O staining, magnification 100×; Figure C shows osteoblasts detected by Alizarin Red staining, magnification 100×; Figure D shows Alcian blue staining of chondrocytes, scale bar 200μm, magnification: 100×; Figure E shows the surface marker spectrum of BMSC, CD45 expression is negative; Figure F shows CD11b expression is negative; Figure G shows CD29 positive expression, and Figure H shows LY6A positive expression;

[0021] Figure 6 The comparison chart of drug encapsulation efficiency of CFPM at different mass ratios of curcumin to polymer;

[0022] Figure 7 This is a comparison of the drug loading of CFPM in the presence of different mass ratios of curcumin and polymer;

[0023] Figure 8 is the degradation curve of microspheres;

[0024] Fig. 9 To screen the optimal cell density for the combination of cells and microspheres; Figure A is a low cell density (1×10 6 Figure B shows the number of cells cultured at high cell density (1×10 7 The number of cells of bone marrow mesenchymal stem cells and BMSC microspheres cultured with 10 cells / mL;

[0025] Fig.10 This is a morphology image of porous microspheres loaded with stem cells observed using a laser confocal microscope;

[0026] Fig.11 This is a comparison of the growth and activity of stem cells with porous microspheres loaded with curcumin;

[0027] Fig.12 This is a macroscopic image of the wound surface of diabetic mice;

[0028] Fig.13 The stem cell composite material of the present invention can better promote the healing of diabetic wounds, and the wound healing rate analysis chart;

[0029] Fig.14 HE staining to detect the improvement of BMSC@CFPM on the pathological morphology of wounds in diabetic mice;

[0030] Fig.15 Comparison chart for wound length analysis;

[0031] Fig.16 This is a comparison chart of dermis thickness analysis;

[0032] Fig.17 This is a comparison chart of the number analysis of subcutaneous appendages;

[0033] Fig.18 Masson staining to observe the collagen production of BMSC@CFPM in improving diabetic wounds;

[0034] Fig.19 This is a comparison chart of Masson staining observation data analysis;

[0035] Fig. 20 Picrosirius red staining was used to observe the collagen maturity comparison of BMSC@CFPM in improving diabetic wounds;

[0036] Fig.21 This is a comparison chart of Picrosirius red staining data analysis. DETAILED DESCRIPTION

[0037] In order to more clearly understand the above-mentioned objectives, features and advantages of the present invention, the scheme of the present invention will be further described below. It should be noted that the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.

[0038] In the following description, many specific details are set forth to facilitate a full understanding of the present invention, but the present invention may also be implemented in other ways different from those described herein; it is obvious that the embodiments in the specification are only part of the embodiments of the present invention, rather than all of the embodiments.

[0039] The primary invention purpose of the embodiment of the present invention is to propose a stem cell composite material that can be used as a drug for treating diabetic foot. The embodiment of the present invention found through innovative research that the porous microspheres loaded with curcumin are used as a drug delivery system for mesenchymal stem cells, and the mesenchymal stem cells are further loaded, which not only overcomes the defects of low solubility, poor stability, low absorption rate, fast metabolism, short half-life, and low bioavailability of curcumin, but also ensures the viability and activity of mesenchymal stem cells. The synergistic effect of curcumin and mesenchymal stem cells has a significant therapeutic effect on difficult-to-heal wounds.

[0040] Specifically, the composite material includes a drug-carrying system and mesenchymal stem cells loaded on the drug-carrying system, wherein the drug-carrying system is a porous microsphere (CFPM) loaded with curcumin; and the material of the porous microspheres in the porous microspheres loaded with curcumin is four-arm star-shaped polylactide.

[0041] In an embodiment of the present invention, the drug delivery system is a porous microsphere loaded with curcumin, and the release of the drug in the porous microsphere may have two mechanisms: diffusion and degradation release. In the diffusion-controlled release process, the drug adsorbed on the surface of the porous microsphere is released by diffusion of the microsphere pores, and the degradation release is controlled by the destruction of the skeleton structure of the porous microsphere. In an embodiment of the present invention, curcumin is directly embedded in the porous microsphere, and the amount of curcumin released is calculated after removing the curcumin remaining on the surface. At this time, the release mechanism of curcumin is mainly degradation release. Experimental results show that the amount of curcumin released in the drug delivery system within 30 days is half of the total amount, indicating that the drug delivery system of the embodiment of the present invention has good sustained release ability.

[0042] Preferably, the mesenchymal stem cells are bone marrow mesenchymal stem cells.

[0043] As a preferred embodiment of the stem cell composite material of the present invention, the particle size of the porous microspheres loaded with curcumin is 20 to 80 μm, and the diameter of the pores is 3 to 10 μm. The porous microspheres loaded with curcumin have a flower-like fiber binding structure, and the gaps between the flower-like structures can be 3 to 10 μm, which increases the surface roughness. The diameter of the fiber is on the nanoscale, and the fiber orientation forms a unique micro / nano structure. This unique micro / nano structure promotes the contact guidance of cells.

[0044] As a preferred embodiment of the stem cell composite material of the present invention, the preparation method of the composite material includes at least the following steps:

[0045] S1. preparing porous microspheres loaded with curcumin;

[0046] S2, expelling the air in the pores of the porous microspheres loaded with curcumin;

[0047] S3, placing the porous microspheres loaded with curcumin on a solid culture medium, and filling the pores of the porous microspheres loaded with curcumin with a liquid culture medium;

[0048] S4. Add a cell suspension of bone marrow mesenchymal stem cells to a solid culture medium and culture for a period of time to obtain a stem cell composite material. In S1 of the preparation method of the stem cell composite material, porous microspheres loaded with curcumin are prepared by stirring a four-arm polylactic acid raw material and curcumin in an organic solvent at a mass ratio of 10 to 20:1. When the curcumin dosage increased from 5% to 10%, the encapsulation rate decreased from 93.9% to 79.8%, indicating that when the mass of the porous microspheres remains unchanged, the less the dosage, the higher the encapsulation efficiency. In general, CFPM has a good encapsulation effect in the face of different dosages. Preferably, the mass volume ratio of the four-arm polylactic acid raw material to the organic solvent is 0.2g:10mL.

[0049] The porous microspheres loaded with curcumin prepared in the embodiment of the present invention have a relative molecular mass that is constantly decreasing within 30 days, and the average relative molecular mass is rapidly decreasing in the first 15 days, and the average relative molecular mass changes slowly from 15 days to 30 days, indicating that the drug delivery system of the present invention has a technical effect of sustained release.

[0050] In S2 of the preparation method of the stem cell composite material, the porous microspheres loaded with curcumin are placed in a drying oven and evacuated for 1 to 3 hours, and then immersed in water for storage.

[0051] In S3 of the preparation method of the stem cell composite material, the porous microspheres loaded with curcumin are transferred to a container containing a solid culture medium, and a liquid culture medium is added and soaked for 1 to 3 hours, and then all the liquid is sucked out;

[0052] Preferably, 5 to 20 mg, preferably 10 mg, of porous microspheres loaded with curcumin are added to each container.

[0053] In the preparation method of the stem cell composite material, the solid culture medium is selected from agarose solid culture medium, the liquid culture medium is selected from DMEM culture medium, and the cell suspension contains stem cell culture medium.

[0054] In S4 of the method for preparing the stem cell composite material, the concentration of the cell suspension is 10 6 ~10 7 cells / mL, add serum-containing medium after 1 to 3 hours of culture, and continue to culture for 2 to 4 days. 7 Cell proliferation can also be guaranteed when inoculated at a high density of 1.5 cells / mL.

[0055] In S4 of the method for preparing the stem cell composite material, the volume of the cell suspension may be 10 to 100 μL, and preferably 50 μL.

[0056] In S4 of the method for preparing the stem cell composite material, the amount of serum-containing medium added may be 1 to 3 μL, and preferably 1.5 mL.

[0057] The embodiment of the present invention also relates to the use of the above-mentioned stem cell composite material in the preparation of a medicine for treating diabetic foot.

[0058] The present invention also relates to the use of the above-mentioned stem cell composite material in the preparation of a drug for treating and promoting wound healing. Animal experiments have confirmed that the stem cell composite material of the present invention can better promote the healing of diabetic wounds, significantly promote the collagen production of diabetic wounds, facilitate wound healing, and induce efficient collagen remodeling and skin maturation.

[0059] The embodiment of the present invention combines the self-renewal and self-replication properties of mesenchymal stem cells with a drug delivery system (porous microspheres loaded with curcumin) to act on difficult-to-heal wounds. Therefore, the stem cell composite material of the embodiment of the present invention can be used as a new candidate drug for difficult-to-heal wounds.

[0060] Example 1

[0061] This example is used to illustrate the preparation method of porous microspheres loaded with curcumin:

[0062] (1) Preparation of raw porous microspheres:

[0063] The reaction equation is as follows:

[0064]

[0065] Add 43.2g of L-lactide to a three-necked flask, heat the oil bath to 125°C, evacuate the original gas, and flush with nitrogen. Maintain for 5 minutes. Then add 120mg of Snoct2 and 183.8mg of pentaerythritol (or none), evacuate the gas, flush with nitrogen, raise the temperature to 140°C, react for 24 hours, and obtain four-arm polylactic acid (four-arm star polylactide, PLA-4). Dissolve the four-arm polylactic acid in CH2Cl2 and pour into a large amount of alcohol for precipitation. Place the precipitate in a 60°C oven, vacuum dry for 10 hours, collect, and store in a drying tank.

[0066] (2) Preparation of porous microspheres loaded with curcumin: Weigh 200 mg of PLA-4 raw material, dissolve 20 mg of curcumin in 10 mL of THF, and stir at 50°C for 5 min until clear. Add 30 mL of glycerol dropwise to obtain an emulsion. Freeze the emulsion in liquid nitrogen for 10 min, take it out, thaw it, pour it into 1000 mL of 0°C ultrapure water, leave it for 24 h, filter it, wash it, and freeze it for later use.

[0067] Results: Curcumin was loaded inside and outside the porous microspheres by physical adsorption to prepare porous microspheres loaded with curcumin, namely drug-loading system. Microscopic observation showed that the morphology was in the shape of a bouquet, which was called curcumin-loaded bouquet microspheres (CFPM).

[0068] The morphology of curcumin-loaded bouquet microspheres (CFPM) was observed by laser confocal microscopy. Figure 1 Figure A is a 2D image of curcumin-loaded bouquet microspheres (CFPM), and Figure B is a 3D image of curcumin-loaded bouquet microspheres (CFPM). CFPM is basically circular and contains fluorescent curcumin.

[0069] Example 2

[0070] This example is used to illustrate the microscopic characterization and release of porous microspheres (FPM), drug delivery system (porous microspheres loaded with curcumin)

[0071] 1. Weigh 0.20g PLLA-4 (poly L-lactide), dissolve it in 10mL THF, stir at 50℃ for 5min until the solution becomes clear. Strictly control the rotation speed and add 30mL of glycerol. Quickly freeze the obtained emulsion in liquid nitrogen for 10min, then take it out. After melting at room temperature, pour it into 1000mL of ice-water mixture and leave it overnight. Filter and wash with ultrapure water several times, put it into a freeze dryer, freeze-dry the microspheres, seal and store them. The obtained porous microspheres are named FPM. The morphology of the microspheres was characterized by scanning electron microscopy (SEM), as shown in the following figure. Figure 2 As shown in A, B, and C; A is an electron microscope image of FPM; B and C are magnified details of FPM;

[0072] 2. The porous microspheres loaded with curcumin were prepared according to the method of Example 1 and named CFPM. The morphology of the microspheres was characterized by scanning electron microscopy (SEM). Figure 3 As shown in D, E, and F, D is the electron microscope image of CFPM; E and F are magnified details of CFPM;

[0073] like Figure 2 , Figure 3 As shown in the figure, the two types of microspheres prepared by AF from different materials have the same surface morphology characteristics. Curcumin-loaded bouquet microspheres (CFPM) and bouquet microspheres (FPM) have flower-like fiber binding structures, and the gaps between the flower-like structures are about 7μm, which greatly increases the surface roughness. The diameter of the fiber is on the nanoscale, the width of the flower-like binding structure is <10μm, and the fiber orientation forms a unique micro / nano structure. This unique micro / nano structure promotes cell contact guidance ( Figure 2 C. Figure 3 F).

[0074] 3. Release amount

[0075] 30 mg of curcumin-loaded bouquet microspheres (CFPM) were accurately weighed and placed in 2.0 mL of PBS (0.1 M, pH = 7.35), and placed in a shaker at 37° C. and 80 rpm, protected from light.

[0076] The mixture was centrifuged at 1000 rps, and the supernatant was taken. The content of curcumin in the degradation medium was determined by UV spectrophotometer, and the release amount of curcumin during the in vitro degradation process was calculated.

[0077] The release amount of curcumin from curcumin-loaded bouquet microspheres (CFPM) is as follows Figure 4 As shown in Figure 3, CFPM released 32% of curcumin in 7 days and 47% of curcumin in 30 days without sudden release, indicating that CFPM has good sustained release ability.

[0078] Example 3

[0079] This example is used to illustrate the preparation method of stem cell composite material:

[0080] 1. Extraction of mouse bone marrow mesenchymal stem cells

[0081] (1) Soak the neonatal mice in 75% alcohol for 10 min and then wash with PBS.

[0082] (2) Remove the four legs and the tail, use tweezers to tear open the skin on the limbs, find the shoulder joints of the forelimbs and the femur of the hind limbs, remove the limbs, carefully remove the muscle tissue, and take out the femur and tibia.

[0083] (3) Place the cleaned bones in pre-cooled anticoagulant buffer.

[0084] (4) After the bones are collected, prepare a dish, add an appropriate amount of collagenase, transfer the bones to the dish, cut them into 1-2 mm pieces, transfer them to a 15 mL centrifuge tube, rinse the dish with collagenase, transfer them to the centrifuge tube, tighten it, and seal it with a sealing film.

[0085] (5) Enzymatic hydrolysis was performed at 200 rpm and 37°C for 45 min to 1 h. The cells were centrifuged at 300 g (1200 r) for 10 min, and the supernatant was discarded. The cells were resuspended and mixed with an appropriate amount of special culture medium, and then the cells were seeded together with the bone slices in a culture dish. Two to three mice were placed in one T25 culture flask, and the culture medium was changed after 2 to 3 days.

[0086] The experimental results obtained are as follows Figure 5 As shown: The extracted stem cells are spindle-shaped. Figure 5 A. Oil red O staining showed that the cells have adipogenic differentiation function ( Figure 5 B), Alizarin red staining showed that the cells have osteogenic differentiation function ( Figure 5 C), Alcian blue staining showed that the cells have chondrocyte differentiation function ( Figure 5 D) Flow cytometry results showed that CD45 and CD11b were negative (0.83%, 0.31%). CD29 and LY6A were positive (96.38%, 99.93%). Figure 5 EH).

[0087] 2. Explain the preparation method of stem cell composite material:

[0088] (1) Weigh 10 mg of the porous microspheres (CFPM) loaded with curcumin (prepared in Example 1), wrap them with gauze and insert them into 5 mL of EP, add deionized water to completely immerse the CFPM, put the EP tube into a vacuum drying oven, evacuate and keep it for 2 hours to remove the air inside the CFPM, remove the gauze, immerse the CFPM in water, and still place it in the EP tube. Sterilize the EP tube containing the CFPM with ultraviolet light for 30 minutes. After sterilization, wipe the EP tube with 75% ethanol and move it to a sterile operating table.

[0089] (2) Take a 24-well cell culture plate and add 300 μL of 5 mg / mL agarose solution to each well. After cooling and solidification, transfer the CFPM in the EP tube into the culture plate and soak it in DMEM culture medium for 2 h. After that, completely aspirate all the liquid and set aside.

[0090] (3) The stem cells prepared in Example 2 (the cells verified to be bone marrow mesenchymal stem cells by testing the stem cell tri-differentiation function) were co-cultured with the porous microspheres loaded with curcumin: the cells were inoculated onto the porous microspheres loaded with curcumin after the above treatment, and 50 μL of 10 6 cells / mL of cell suspension, the cell suspension is prepared with stem cell culture medium (mesencult basal medium, MOUSE, STEMCELL). The culture plate is placed in an incubator for 2 hours to allow the cells to fully adhere to the CFPM surface, and then 1.5 mL of serum-containing culture medium is added, and the culture is continued for 2 to 4 days, and the medium is changed every two days to obtain a stem cell composite material (BMSC@CFPM).

[0091] Example 4

[0092] This example is used to illustrate the packaging capability of the drug delivery system (CFPM):

[0093] The method for preparing the drug delivery system (CFPM) according to Example 1:

[0094] Four-arm polylactic acid raw material and curcumin were prepared in a mass ratio of 10:1 (curcumin 10%) and 20:1 (curcumin 5%) to obtain two drug delivery systems (CFPM) for encapsulation capacity testing. The experimental method is as follows:

[0095] Weigh an appropriate amount of CFPM microspheres, dissolve them in DMSO, and measure the absorbance with an enzyme marker. Calculate its content according to the curcumin standard curve, and calculate the encapsulation efficiency (DLC%) and drug loading efficiency (DLE%) according to formulas 4-1 and 4-2. The calculation formula is as follows:

[0096]

[0097]

[0098] Wherein, M0 is the drug content in the carrier, M N is the total mass of the final drug-loaded microspheres, M c Indicates the initial dosage.

[0099] The experimental results are as follows Figure 6 , 7 As shown: Figure 6 Drug encapsulation efficiency of CFPM with different mass ratios of curcumin to polymer. Figure 7 Drug loading capacity of CFPM in the presence of different mass ratios of curcumin to polymer.

[0100] like Figure 6 , Figure 7 As shown, according to formulas 4-1 and 4-2, the drug loading and encapsulation efficiency of curcumin are calculated. When the curcumin dosage is 5%, the CFPM drug loading rate is 4.7%, and the encapsulation efficiency is 93.9%; when the curcumin dosage is 10%, the CFPM microsphere drug loading rate is 8.0%, and the encapsulation efficiency is 79.8%. Faced with different dosages, CFPM has a good encapsulation effect.

[0101] Example 5

[0102] This example is used to illustrate the degradation of microspheres:

[0103] The experimental process is as follows: weigh an appropriate amount of FPM and drug delivery system (CFPM) prepared in Example 2, dissolve them in DMSO, and measure the absorbance with an enzyme marker. Calculate its content according to the curcumin standard curve, and calculate the encapsulation efficiency (D) according to formulas 4-1 and 4-2. LC %) and drug loading rate (D LE %).

[0104] The experimental results are as follows Figure 8 As shown: Figure 8 It can be seen that the degradation law of polylactic acid microspheres is that the relative molecular weight of the two polylactic acid microspheres is constantly decreasing within 30 days. Carefully observing the law of molecular weight reduction of the two microspheres, it is found that the average relative molecular weight of each microsphere is rapidly decreasing in the first 15 days, and the average relative molecular weight of the two microspheres changes slowly from 15 days to 30 days.

[0105] Example 6

[0106] Screening for the optimal cell density for cell binding to porous microspheres (FPM):

[0107] The stem cell composite material was prepared according to the method of Example 3, and the cell suspension concentration of bone marrow mesenchymal stem cells was compared with 10 6 cells / mL、1×10 7 cells / mL in 2D environment and porous microspheres (FPM).

[0108] like Fig. 9 As shown, compared with normal culture of bone marrow mesenchymal stem cells (2D environment), at low cell density (1×10 6 cells / mL) Fig. 9 A) The proliferation rate of BMSCs in FPM (3D environment) is low. However, when BMSCs are cultured at 1×10 7 cells / mL at high density inoculation ( Fig. 9 B), there is a significant difference in cell growth on day 2, and the proliferation rate of FPM cells increased on day 3. There is no significant difference in the proliferation rate of 2D and 3D cultures on day 7. Cells in 2D culture can quickly reach contact growth inhibition, while cells in FPMs can proliferate in a richer internal space. This shows that FPM can provide a suitable microenvironment for the proliferation of stem cells, so high-density bone marrow mesenchymal stem cells have rapid proliferation and are not affected by contact inhibition.

[0109] Example 7

[0110] This example is used to illustrate the activity of stem cells in the stem cell composite material:

[0111] 1. Observe the morphology of the stem cell composite material of Example 3 using a laser confocal microscope:

[0112] After stem cells and porous microspheres loaded with curcumin were co-cultured for 1 day, the cells were stained with fluorescent diethyl ester. In a 24-well plate, 50 μL of 5 mg / mL fluorescent diethyl ester was added to each well, incubated in a 37°C incubator for 20 minutes, transferred to a 35 mm culture dish, and observed under a laser confocal microscope. The morphology of porous microspheres loaded with stem cells observed under a laser confocal microscope is shown in the figure. Fig.10 As shown. The results showed that drug-loaded microspheres (lactic acid microspheres with both bouquet-like structure and curcumin) have the effect of promoting cell adhesion. After 24 hours of co-culture, the nucleus was directly stained with DAPI and the number of cells was observed by confocal microscopy. There was no significant effect on cell proliferation compared with ordinary culture.

[0113] 2. Comparison of stem cell growth and stem cell activity:

[0114] Experimental method: Stem cells and porous microspheres (FPM) were co-cultured for four hours. RNA was extracted from cells loaded in each group of microspheres. The activity of stem cells was detected by qQT-PCR experiment, and the expression of Oct 4, Nanog, and Sox 2 mRNA was detected to obtain the experimental results. Fig.11 As shown in Figure 2, it can maintain stronger stem cell activity than 2D culture, and the mRNA expressions of genes representing stem cell stemness, such as Oct 4, Nanog, and Sox 2, are significantly increased.

[0115] Example 8

[0116] This example is used to illustrate the effect of stem cell composite materials on diabetic wounds that are difficult to heal.

[0117] 1. Experimental grouping and model preparation

[0118] 1.1. Conventional Diabetes Model (Type I) STZ was injected intraperitoneally at a dose of 100 mg / kg. After successful modeling, the rats were maintained for one month.

[0119] 1.2. Make a diabetic wound model, anesthetize, prepare the skin, disinfect, and use an 8mm sterile punch to make the wound model.

[0120] Experimental groups:

[0121] Model group: DIA;

[0122] Stem cell group: BMSC;

[0123] Drug-loaded microspheres loaded with stem cells (prepared in Example 3) group: BMSC@CFPM;

[0124] Dosage method: injection at 8 points around the wound, once every 3 days, with a volume of about 160 μL, and a constant number of cells per group of 2×10 5 , a total of 5 injections;

[0125] 2. Experimental methods

[0126] Disinfection, photography, corresponding drug treatment, single cage feeding. Photography was taken daily, and dressing was changed every other day. When the wound healed 50% and 80%, the sample was taken, half was fixed, and the other half was stored at -80℃. It was fixed in 4% paraformaldehyde and embedded in paraffin, and then 5μm thick sections were cut from the paraffin samples and fixed on slides for staining.

[0127] 3. Experimental results:

[0128] (1) Macroscopic images of wound surfaces in diabetic mice Fig.12 As shown, the stem cell composite material of the present invention can better promote the healing of diabetic wounds. The wound healing rate analysis is as follows Fig.13 shown.

[0129] Wound healing rate = (0d area - area at a certain time point) / 0d area * 100%

[0130] The experimental results show that curcumin lactate microspheres loaded with mesenchymal stem cells (BMSC@CFPM) can significantly promote wound healing from day 3 (P<0.001), and also have a significant effect on days 3 and 7 compared with stem cells (P<0.05, P<0.01). BMSC@CFPM can better promote wound healing in diabetic patients.

[0131] (2) Tissue staining: H&E staining, Masson staining, and immunostaining

[0132] (2.1) H&E and Masson staining: Hematoxylin and eosin (H&E) and Masson trichrome staining were performed for histological analysis according to the manufacturer's instructions. The slides were then observed under a Nikon FHEPSE 80i (Nikon, Japan) microscope. H&E and Masson staining are used to observe the wound healing by observing the formation of granulation tissue, which is usually included in the second phase (proliferative phase) of wound healing.

[0133] HE staining detected that BMSC@CFPM improved the pathological morphology of wounds in diabetic mice. Fig.14 As shown in the figure, HE staining results showed that compared with the model group, the stem cell composite material group (BMSC@CFPM) of the present invention could significantly reduce the wound area at 7 days, and the effect was more obvious than that of the stem cell group (P<0.001). The wound length analysis was as follows: Fig.15 As shown, dermal thickness analysis is as follows Fig.16 As shown, the number of subcutaneous appendages was analyzed as Fig.17 The thickness of the epidermis also increased significantly (P<0.001), and the skin appendages, such as hair follicles, also increased significantly (P<0.001).

[0134] Masson staining observation of BMSC@CFPM improving collagen production in diabetic wounds Fig.18 As shown, Masson staining results showed that BMSC@CFPM treatment increased collagen deposition and accelerated wound healing.

[0135] Masson staining observation data analysis Fig.19 As shown, Masson staining observed that BMSC@CFPM improved collagen production in diabetic wounds: Masson staining results showed that BMSC@CFPM could significantly promote collagen production in diabetic wounds at 7 days and 21 days, which was beneficial to wound healing.

[0136] Fig. 20 Picrosirius red staining was used to observe the collagen maturation of BMSC@CFPM in improving diabetic wounds. Fig. 20 As shown, Picrosirius red staining data analysis is as follows Fig.21 shown.

[0137] Image J software was used for optical density analysis of different colors, and GraphPad Prism 5.0 software was used for statistical analysis. The results of picrosirius red staining showed that in the early stage of wound healing, the deposition of collagen (mainly immature collagen-III) was enhanced to cover the wound site and prevent further damage. After tissue remodeling, collagen-III was gradually replaced by collagen-I, which was mainly present in mature skin tissue. Collagen remodeling was evaluated by licorice red staining, indicating that the native collagen in diabetic wounds was destroyed and presented an irregular and fibrous structure. The enhanced deposition of collagen-I in the BMSC@CFPM group indicated that BMSC@CFPM could induce efficient collagen remodeling and skin maturation.

[0138] The above description is only a specific embodiment of the present invention, so that those skilled in the art can understand or implement the present invention. Various modifications to these embodiments will be apparent to those skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments described herein, but should conform to the widest scope consistent with the principles and novel features disclosed herein.

Claims

1. A stem cell composite material, It is characterized in that The composite material comprises a drug-carrying system and mesenchymal stem cells loaded on the drug-carrying system, wherein the drug-carrying system is a porous microsphere loaded with curcumin; the material of the porous microspheres in the porous microspheres loaded with curcumin is four-arm star-shaped polylactide; Preferably, the mesenchymal stem cells are bone marrow mesenchymal stem cells.

2. The stem cell composite material according to claim 1, It is characterized in that The particle size of the porous microspheres loaded with curcumin is 20-80 μm, and the diameter of the pores is 3-10 μm.

3. The stem cell composite material according to claim 1 or 2, It is characterized in that The method for preparing the composite material comprises at least the following steps: S1. preparing porous microspheres loaded with curcumin; S2, discharging the air in the pores of the porous microspheres loaded with curcumin; S3, placing the porous microspheres loaded with curcumin on a solid culture medium, and filling the pores of the porous microspheres loaded with curcumin with a liquid culture medium; S4. Adding a cell suspension of bone marrow mesenchymal stem cells to the solid culture medium and culturing for a period of time to obtain the stem cell composite material.

4. The stem cell composite material according to claim 3, It is characterized in that In S2, the porous microspheres loaded with curcumin are placed in a drying oven and evacuated for 1 to 3 hours, and then immersed in water for storage.

5. The stem cell composite material according to claim 3, It is characterized in that In S3, the porous microspheres loaded with curcumin are transferred to a container containing a solid culture medium, and a liquid culture medium is added to soak for 1 to 3 hours, and then all the liquid is sucked out; Preferably, 10 mg of the porous microspheres loaded with curcumin are added into each of the containers.

6. The stem cell composite material according to claim 5, It is characterized in that The solid culture medium is selected from agarose solid culture medium, the liquid culture medium is selected from DMEM culture medium, and the cell suspension contains stem cell culture medium.

7. The stem cell composite material according to claim 3, It is characterized in that In S4, the concentration of the cell suspension is 10 6 ~10 7 cells / mL, add serum-containing medium after 1 to 3 hours of culture, and continue to culture for 2 to 4 days; Preferably, the volume of the cell suspension is 50 μL; More preferably, the amount of serum-containing culture medium added is 1.5 mL.

8. The stem cell composite material according to claim 3, It is characterized in that In S1, the porous microspheres loaded with curcumin are prepared by stirring a four-arm polylactic acid raw material and curcumin in an organic solvent at a mass ratio of 10 to 20:1; Preferably, the mass volume ratio of the four-arm polylactic acid raw material to the organic solvent is 0.2 g:10 mL.

9. Use of the stem cell composite material according to any one of claims 1 to 8 in the preparation of a drug for treating diabetic foot.

10. Use of the stem cell composite material according to any one of claims 1 to 8 in the preparation of a drug for treating and promoting wound healing.